MC2307A1 - Inactivateurs de l'uracile reductase - Google Patents

Inactivateurs de l'uracile reductase

Info

Publication number
MC2307A1
MC2307A1 MC912307D MC2307D MC2307A1 MC 2307 A1 MC2307 A1 MC 2307A1 MC 912307 D MC912307 D MC 912307D MC 2307 D MC2307 D MC 2307D MC 2307 A1 MC2307 A1 MC 2307A1
Authority
MC
Monaco
Prior art keywords
uracile
halo
inactivators
reductase
substd
Prior art date
Application number
MC912307D
Other languages
English (en)
French (fr)
Inventor
Thomas Spector
David Porter
Saad Rahim
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10682770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MC2307(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of MC2307A1 publication Critical patent/MC2307A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Springs (AREA)
  • Vibration Dampers (AREA)
  • Semiconductor Lasers (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
  • Transformer Cooling (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MC912307D 1990-09-26 1991-09-25 Inactivateurs de l'uracile reductase MC2307A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909020930A GB9020930D0 (en) 1990-09-26 1990-09-26 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
MC2307A1 true MC2307A1 (fr) 1993-09-27

Family

ID=10682770

Family Applications (1)

Application Number Title Priority Date Filing Date
MC912307D MC2307A1 (fr) 1990-09-26 1991-09-25 Inactivateurs de l'uracile reductase

Country Status (30)

Country Link
US (5) US6268374B1 (no)
EP (2) EP0985415A1 (no)
JP (2) JP2682739B2 (no)
KR (1) KR100222329B1 (no)
AT (1) ATE190489T1 (no)
BR (1) BR1100356A (no)
CA (2) CA2390654A1 (no)
CZ (4) CZ16196A3 (no)
DE (1) DE69132052T2 (no)
DK (1) DK0550580T3 (no)
ES (1) ES2143465T3 (no)
FI (1) FI112601B (no)
GB (1) GB9020930D0 (no)
GR (1) GR3033388T3 (no)
HK (1) HK1004188A1 (no)
HU (1) HU219589B (no)
IE (1) IE20010101A1 (no)
IL (2) IL99562A (no)
MC (1) MC2307A1 (no)
MY (1) MY128980A (no)
NO (2) NO313175B1 (no)
NZ (2) NZ250799A (no)
PT (1) PT99041B (no)
RU (1) RU2194511C2 (no)
SG (1) SG47912A1 (no)
SK (1) SK281894B6 (no)
TW (1) TW271397B (no)
UA (1) UA42679C2 (no)
WO (1) WO1992004901A1 (no)
ZA (1) ZA917667B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
CA2103050A1 (en) * 1991-05-15 1992-11-16 Yung-Chi Cheng Determination of prodrugs metabolizable by the liver and therapeutic use thereof
GB9322795D0 (en) * 1993-11-05 1993-12-22 Wellcome Found Novel compounds
US6849602B1 (en) * 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US7026301B2 (en) * 2002-10-17 2006-04-11 New York University Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
US20080255168A1 (en) * 2004-12-03 2008-10-16 Adherex Technologies, Inc. Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
CN102441170A (zh) * 2004-12-03 2012-05-09 阿迪赫里克斯技术公司 与5-fu和5-fu前药组合施用dpd抑制剂的方法
AU2012200856B2 (en) * 2004-12-03 2013-10-10 Adherex Technologies Inc. Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
WO2009100367A2 (en) * 2008-02-06 2009-08-13 Adherex Technologies Inc. Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome
EA201270551A1 (ru) * 2009-10-14 2012-12-28 Эдхиэрекс Текнолоджиз, Инк. Лечение нейротоксичности, ассоциированной с комбинациями 5-fu или его пролекарств с ингибиторами dpd
US10556872B2 (en) 2017-03-17 2020-02-11 Hampton University Fatty acid synthase inhibitors and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324126A (en) * 1963-08-07 1967-06-06 Univ Kansas State Production of 5-trifluoromethyluracil
US4124765A (en) 1975-05-13 1978-11-07 Ono Pharmaceutical Co., Ltd. 5-Fluorouracil derivatives
DE2522369A1 (de) 1975-05-21 1976-12-02 Ono Pharmaceutical Co 5-fluoruracilderivate und verfahren zu ihrer herstellung
DD122381A1 (no) * 1975-10-03 1976-10-05
JPS55111420A (en) * 1979-02-20 1980-08-28 Ono Pharmaceut Co Ltd Antitumorigenic agent
US4381344A (en) 1980-04-25 1983-04-26 Burroughs Wellcome Co. Process for producing deoxyribosides using bacterial phosphorylase
JPS6094971A (ja) * 1983-10-31 1985-05-28 Sagami Chem Res Center ５−ペルフルオロアルキルウラシル類の製造方法
US4719214A (en) 1985-07-25 1988-01-12 Southern Research Institute Carbocyclic analogues of thymine nucleosides
GB8629892D0 (en) * 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
US4863927A (en) 1987-05-11 1989-09-05 Merck & Co., Inc. 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils
US4874602A (en) 1988-02-22 1989-10-17 Paul Calabresi Reduction of the severity 3'-azido-3'-deoxythymidine-induced anemia using benzylacyclouridine
DE68918804T2 (de) * 1988-03-31 1995-02-23 Mitsubishi Chem Ind Acyclische 6-substituierte pyrimidin nukleosid-abkömmlinge und antivirale mittel, die dieselben als aktive mittel enthalten.
US5077280A (en) 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
US5198539A (en) * 1988-08-19 1993-03-30 Burroughs Wellcome Co. 5'-esters of 2',3'-dideoxy-3'-fluoro-5-ethynyluridine
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
ATE154359T1 (de) * 1988-08-25 1997-06-15 Yoshitomi Pharmaceutical 2'-methylidenpyrimidinnukleosidverbindungen, ihre verwendung und verfahren zu ihrer herstellung
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
US5643913A (en) * 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds
JP3094036B2 (ja) * 1990-07-19 2000-10-03 ザ ウエルカム ファウンデーション リミテッド 酵素不活性化剤
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations

Also Published As

Publication number Publication date
FI931337A0 (fi) 1993-03-25
NO980717D0 (no) 1998-02-20
NO980717L (no) 1993-03-25
US20020042392A1 (en) 2002-04-11
US20070078106A1 (en) 2007-04-05
RU2194511C2 (ru) 2002-12-20
KR100222329B1 (en) 1999-10-01
CZ16196A3 (en) 1996-05-15
NO313175B1 (no) 2002-08-26
SK23393A3 (en) 1993-07-07
CZ288520B6 (cs) 2001-07-11
JPH1045623A (ja) 1998-02-17
US5817664A (en) 1998-10-06
WO1992004901A1 (en) 1992-04-02
CA2390654A1 (en) 1992-04-02
GR3033388T3 (en) 2000-09-29
JP2682739B2 (ja) 1997-11-26
GB9020930D0 (en) 1990-11-07
NZ239927A (en) 1995-11-27
ATE190489T1 (de) 2000-04-15
CA2092435A1 (en) 1992-03-27
CZ170995A3 (en) 1995-12-13
US7704971B2 (en) 2010-04-27
US6297223B1 (en) 2001-10-02
UA42679C2 (uk) 2001-11-15
CA2092435C (en) 2002-11-12
ZA917667B (en) 1993-03-25
EP0550580B1 (en) 2000-03-15
EP0985415A1 (en) 2000-03-15
BR1100356A (pt) 2003-02-25
CZ288515B6 (cs) 2001-07-11
IL99562A0 (en) 1992-08-18
NO931118L (no) 1993-03-25
US6268374B1 (en) 2001-07-31
SG47912A1 (en) 1998-04-17
TW271397B (no) 1996-03-01
MY128980A (en) 2007-03-30
JPH06504263A (ja) 1994-05-19
PT99041A (pt) 1992-08-31
CZ50693A3 (en) 1994-02-16
DE69132052D1 (de) 2000-04-20
NZ250799A (en) 1995-11-27
HUT63765A (en) 1993-10-28
IL99562A (en) 1999-11-30
PT99041B (pt) 1999-02-26
DK0550580T3 (da) 2000-12-04
IL121947A0 (en) 1998-03-10
US7119096B2 (en) 2006-10-10
NO931118D0 (no) 1993-03-25
EP0550580A1 (en) 1993-07-14
AU654505B2 (en) 1994-11-10
JP3003993B2 (ja) 2000-01-31
SK281894B6 (sk) 2001-09-11
ES2143465T3 (es) 2000-05-16
HU9300863D0 (en) 1993-06-28
HK1004188A1 (en) 1998-11-20
DE69132052T2 (de) 2000-08-03
FI931337A (fi) 1993-03-25
HU219589B (hu) 2001-05-28
AU8540591A (en) 1992-04-15
FI112601B (fi) 2003-12-31
CZ16296A3 (en) 1996-05-15
IE20010101A1 (en) 2002-03-20

Similar Documents

Publication Publication Date Title
MC2307A1 (fr) Inactivateurs de l'uracile reductase
ZA953374B (en) Therapy device
CA2334198A1 (en) Irradiation catheter with expandable source
ZA918512B (en) Morphine prodrugs
CA2241722A1 (en) Unitary orthopaedic brace
EP0499467A3 (en) Use of quinones in the treatment of cancer or aids
HU9202095D0 (en) Therapy and vaccine against aids
GB9010420D0 (en) New artist's easel
GR3019866T3 (en) Medicament for treating hyperlipidaemia and/or atherosclerosis
MY111755A (en) Use of 4'-iodo-4'- deoxydoxorubicin for the treatment of amyloidosis.
USD276300S (en) Cabinet door
MX9500231A (es) Analgesicos de 4-arilsoindol.
TW262376B (en) Cabinet with a stoppable drawer
GB9210741D0 (en) Key holder with attached condom drawer
MX9706424A (es) Uso de la moxonidina para el tratamiento de la aterosclerosis.
GR3022441T3 (en) Use of interleukine 10 to produce drugs with a tumour-inhibiting action
AU119855S (en) X-ray beam gradient
AP9100318A0 (en) Inhalation device.